1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. JAPAN PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE
5.1. Introduction
5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
5.3. Corticosteroids
5.4. Acetaminophen
5.5. Opioid
5.5.1. Strong Opioid
5.5.2. Weak Opioid
5.6. Antidepressants
5.7. Anticonvulsant Drugs
5.8. Others
6. JAPAN PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL
6.1. Introduction
6.2. Hospital Pharmacies
6.3. Retail Pharmacies
6.4. Online Pharmacies
7. JAPAN PAIN MANAGEMENT DRUGS MARKET BY INDICATION
7.1. Introduction
7.2. Cancer
7.3. Rheumatoid Arthritis
7.4. Chronic Back Pain
7.5. Post-Operative Pain
7.6. Others
8. JAPAN PAIN MANAGEMENT DRUGS MARKET BY CITY
8.1. Introduction
8.2. Tokyo
8.2.1. By Drug Type
8.2.2. By Distribution Channel
8.2.3. By Indication
8.3. Yokohama
8.3.1. By Drug Type
8.3.2. By Distribution Channel
8.3.3. By Indication
8.4. Osaka
8.4.1. By Drug Type
8.4.2. By Distribution Channel
8.4.3. By Indication
8.5. Nagoya
8.5.1. By Drug Type
8.5.2. By Distribution Channel
8.5.3. By Indication
8.6. Others
8.6.1. By Drug Type
8.6.2. By Distribution Channel
8.6.3. By Indication
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Novartis Pharmaceuticals Corporation (Novartis AG)
10.2. Eli Lilly and Company
10.3. Pfizer Inc.
10.4. GlaxoSmithKline plc
10.5. Sanofi S.A
10.6. Johnson & Johnson
10.7. Viatris Inc.
10.8. DAIICHI SANKYO COMPANY, LIMITED
10.9. Shionogi Inc.
10.10. Asahi Kasei Pharma Corporation.
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations